• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of high-risk follicular lymphoma.

作者信息

Jurczak Wojciech

机构信息

Department of Hematology, Jagiellonian University, Kraków, Poland.

出版信息

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000230. eCollection 2019 Jun.

DOI:10.1097/HS9.0000000000000230
PMID:35309817
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8925667/
Abstract
摘要

相似文献

1
Treatment of high-risk follicular lymphoma.高危滤泡性淋巴瘤的治疗
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000230. eCollection 2019 Jun.
2
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.在接受一线免疫化疗的滤泡性淋巴瘤患者中，基因突变更新预后风险预测：一项前瞻性临床试验的回顾性分析及基于人群的登记处验证。
Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6.
3
Impact of the Follicular Lymphoma International Prognostic Index risk categorization on survival of patients with follicular lymphoma in Pakistani population: a single centre experience.滤泡性淋巴瘤国际预后指数风险分类对巴基斯坦人群中滤泡性淋巴瘤患者生存的影响：单中心经验
J Pak Med Assoc. 2014 May;64(5):563-6.
4
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.基于基因表达谱的滤泡性淋巴瘤患者预后预测评分：三队列回顾性训练和验证分析。
Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20.
5
Assessment of prognostic factors in follicular lymphoma patients.滤泡性淋巴瘤患者预后因素的评估。
Int J Hematol. 2001 Apr;73(3):363-8. doi: 10.1007/BF02981963.
6
Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of follicular lymphoma: a meta-analysis.亚甲基四氢叶酸还原酶基因多态性与滤泡性淋巴瘤风险的关联：一项荟萃分析。
Tumour Biol. 2013 Jun;34(3):1467-71. doi: 10.1007/s13277-013-0670-x. Epub 2013 Jan 29.
7
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.滤泡性淋巴瘤国际预后指数2：由国际滤泡性淋巴瘤预后因素项目制定的滤泡性淋巴瘤新预后指数。
J Clin Oncol. 2009 Sep 20;27(27):4555-62. doi: 10.1200/JCO.2008.21.3991. Epub 2009 Aug 3.
8
Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma.DNA修复基因ERCC2、XRCC1和XRCC3的变异与滤泡性淋巴瘤风险
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):258-65. doi: 10.1158/1055-9965.EPI-05-0583.
9
Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.滤泡性淋巴瘤：初始治疗方法中的诊断和预后考虑因素。
Curr Oncol Rep. 2019 May 23;21(7):63. doi: 10.1007/s11912-019-0808-0.
10
[Recent advances in therapy of follicular lymphoma].[滤泡性淋巴瘤治疗的最新进展]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):250-4. doi: 10.7534/j.issn.1009-2137.2014.01.050.

本文引用的文献

1
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.一线免疫治疗后滤泡淋巴瘤中 PFS24 的预后意义：3 项 CALGB 试验的联合分析。
Cancer Med. 2019 Jan;8(1):165-173. doi: 10.1002/cam4.1918. Epub 2018 Dec 21.
2
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.利妥昔单抗联合来那度胺治疗晚期未经治疗的滤泡性淋巴瘤。
N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.
3
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.利妥昔单抗与滤泡性淋巴瘤转化风险：一项回顾性汇总分析
Lancet Haematol. 2018 Aug;5(8):e359-e367. doi: 10.1016/S2352-3026(18)30090-5. Epub 2018 Jul 4.
4
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.在 GALLIUM 研究中，奥滨尤妥珠单抗或利妥昔单抗联合化疗治疗初治滤泡性淋巴瘤：化疗对疗效和安全性的影响。
J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
5
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.在 GADOLIN 研究中，接受奥滨尤妥珠单抗联合苯达莫司汀诱导及奥滨尤妥珠单抗维持治疗的利妥昔单抗难治性惰性非霍奇金淋巴瘤患者具有总生存获益。
J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.
6
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
7
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.FOLL05 试验的长期结果：比较 R-CVP、R-CHOP 和 R-FM 方案治疗初治晚期症状性滤泡性淋巴瘤患者的疗效。
J Clin Oncol. 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652. Epub 2017 Nov 2.
8
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.利妥昔单抗延长给药方案或再治疗方案用于低肿瘤负荷非滤泡性惰性B细胞非霍奇金淋巴瘤：东部肿瘤协作组E4402方案
Br J Haematol. 2016 Jun;173(6):867-75. doi: 10.1111/bjh.14007. Epub 2016 Mar 11.
9
Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.低强度异基因或自体移植治疗复发3级滤泡性淋巴瘤的长期生存结果
Bone Marrow Transplant. 2016 Jan;51(1):58-66. doi: 10.1038/bmt.2015.223. Epub 2015 Oct 5.
10
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).来那度胺单药与来那度胺联合利妥昔单抗治疗复发性滤泡性淋巴瘤患者的随机试验：CALGB 50401（联盟）
J Clin Oncol. 2015 Nov 1;33(31):3635-40. doi: 10.1200/JCO.2014.59.9258. Epub 2015 Aug 24.